Description: OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company's Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.
Home Page: www.owcpharma.com
2 Ben Gurion Street
Ramat Gan,
5257334
Israel
Phone:
972 72 260 8004
Officers
| Name | Title |
|---|---|
| Mr. Alon Sinai | Chief Operating Officer |
| Dr. Yehuda Baruch | Chief Medical & Regulatory Affairs Officer |
| Mr. Ziv Turner | Chief Exec. Officer |
| Mr. Shmuel De-Saban | CFO & Sec. |
| Dr. Oron Yacoby-Zeevi DVM, Ph.D. | Chief Scientific Officer |
| Prof. Yuval Ramot | Consultant |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 42.2948 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |